Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile

Revista Brasileira de Hematologia e Hemoterapia

Volumn 37, Issue 3, 2015, Pages 184-189

  Ramirez, Pablo ^a   Ocqueteau, Mauricio ^a   Rodriguez, Alejandra ^a   Garcia, Maria Jose ^a   Sarmiento, Mauricio ^a   Ernst, Daniel ^a   Jara, Veronica ^a   Bertin, Pablo ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Hematopoietic stem cell transplantation; Hodgkin disease; Relapse

Indexed keywords

ACICLOVIR; BUSULFAN; CARBOPLATIN; CARMUSTINE; CD34 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FILGRASTIM; FLUCONAZOLE; FLUDARABINE; IFOSFAMIDE; LEVOFLOXACIN; MELPHALAN; PLERIXAFOR; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CAUSE OF DEATH; CHEMOEMBOLIZATION; CHEMOSENSITIVITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKAPHERESIS; LEUKEMIA REMISSION; MALE; MORTALITY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84930089592     PISSN: 15168484     EISSN: 18060870     Source Type: Journal    
DOI: 10.1016/j.bjhh.2015.03.011     Document Type: Article

References (26)

1. Sjöberg J., Halthur C., Kristinsson S.Y., Landgren O., Nygell U.A., Dickman P.W., et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood 2012, 119(4):990-996.
2. Armitage J.O. Early-stage Hodgkin's lymphoma. N Engl J Med 2010, 363(7):653-662.
3. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998, 339(21):1506-1514.
4. Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009, 507-519.
5. Linch D.C., Winfield D., Goldstone A.H., Moir D., Hancock B., McMillan A., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341(8852):1051-1054.
6. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A.M., Haenel M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359(9323):2065-2071.
7. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008, 141(1):3-13.
8. Gajewski J.L1, Phillips G.L., Sobocinski K.A., Armitage J.O., Gale R.P., Champlin R.E., et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996, 14(2):572-578.
9. Milpied N., Fielding A.K., Pearce R.M., Ernst P., Goldstone A.H. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996, 14(4):1291-1296.
10. Raiola A., Dominietto A., Varaldo R., Ghiso A., Galaverna F., Bramanti S., et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant 2014, 49(2):190-194.
11. Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25(5):579-586.
12. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17(4):1244.
13. Center for International Blood and Marrow Transplant Research (CIBMTR). Available from: [cited 02.12.14]. http://www.cibmtr.org/.
14. National Marrow Donor Program® (NMDP). Available from: [cited 02.12.14]. http://www.bethematch.org/.
15. Eichenauer D.A., Engert A., André M., Federico M., Illidge T., Hutchings M., et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(Suppl. 3):iii70-iii75.
16. Bartlett N.L. Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy. Hematol Am Soc Hematol Educ Program 2005, 24:5-51.
17. Lazarus H.M., Loberiza F.R., Zhang M.J., Armitage J.O., Ballen K.K., Bashey A., et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001, 27(4):387-396.
18. Josting A., Müller H., Borchmann P., Baars J.W., Metzner B., Döhner H., et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010, 28(34):5074-5080.
19. Sureda A., Arranz R., Iriondo A., Carreras E., Lahuerta J.J., García-Conde J., et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001, 19(5):1395-1404.
20. Peniket A.J., Ruiz de Elvira M.C., Taghipour G., Cordonnier C., Gluckman E., de Witte T., et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31(8):667-678.
21. Greaves P.J., Gribben J.G. Demonstration of durable graft versus lymphoma effects in Hodgkin's lymphoma. J Clin Oncol 2011, 29(8):952-953.
22. Peggs K.S., Kayani I., Edwards N., Kottaridis P., Goldstone A.H., Linch D.C., et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011, 29(8):971-978.
23. Sureda A., Canals C., Arranz R., Caballero D., Ribera J.M., Brune M., et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012, 97(2):310-317.
24. Sarina B., Castagna L., Farina L., Patriarca F., Benedetti F., Carella A.M., et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010, 115(18):3671-3677.
25. Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011, 117(16):4208-4217.
26. Puga B., Molina J., Andrade A., Guerra C., Ardila A., Alvarez G. First ten hematopoietic stem cell transplants performed in the adult public health service in Chile. Rev Med Chile 2012, 140(9):1207-1212.